Novartis added another wave of US job cuts tied to its East Hanover headquarters, according to a WARN filing. The company said it will lay off about 60 roles later this year, separate from a prior US headquarters reduction plan announced in March. Novartis linked the changes to efforts to evolve oncology, rheumatology, dermatology, and neuroscience field sales teams in the US. The new reductions are scheduled to begin in late July and run through late November, wrapping two separate layoff cycles. The move lands as Novartis faces pressure from a 2026 patent cliff and continues preparing launches in rare kidney disease, while also adapting commercial structures for rare disease medicines.